Abstract:Background: DNA methylation (DNAm) age acceleration (AgeAccel) and cardiac age by 12-lead advanced electrocardiography (A-ECG) are promising biomarkers of biological and cardiac aging, respectively. We aimed to explore the relationships between DNAm age and A-ECG heart age and to understand the extent to which DNAm AgeAccel relates to cardiovascular (CV) risk factors in a British birth cohort from 1946. Results: We studied four DNAm ages (AgeHannum, AgeHorvath, PhenoAge, and GrimAge) and their corresponding AgeAccel. Outcomes were the results from two publicly available ECG-based cardiac age scores: the Bayesian A-ECG-based heart age score of Lindow et al. 2022 and the deep neural network (DNN) ECG-based heart age score of Ribeiro et al. 2020. DNAm AgeAccel was also studied relative to results from two logistic regression-based A-ECG disease scores, one for left ventricular (LV) systolic dysfunction (LVSD), and one for LV electrical remodeling (LVER). Generalized linear models were used to explore the extent to which any associations between biological cardiometabolic risk factors (body mass index, hypertension, diabetes, high cholesterol, previous cardiovascular disease [CVD], and any CV risk factor) and the ECG-based outcomes are mediated by DNAm AgeAccel. We derived the total effects, average causal mediation effects (ACMEs), average direct effects (ADEs), and the proportion mediated [PM] with their 95% confidence intervals [CIs]. 498 participants (all 60-64 years) were included, with the youngest ECG heart age being 27 and the oldest 90. When exploring the associations between cardiometabolic risk factors and Bayesian A-ECG cardiac age, AgeAccelPheno appears to be a partial mediator, as ACME was 0.23 years [0.01, 0.52] p = 0.028 (i.e., PM≈18%) for diabetes, 0.34 [0.03, 0.74] p = 0.024 (i.e., PM≈15%) for high cholesterol, and 0.34 [0.03, 0.74] p = 0.024 (PM≈15%) for any CV risk factor. Similarly, AgeAccelGrim mediates ≈30% of the relationship between diabetes or high cholesterol and the DNN ECG-based heart age. When exploring the link between cardiometabolic risk factors and the A-ECG-based LVSD and LVER scores, it appears that AgeAccelPheno or AgeAccelGrim mediate 10-40% of these associations. Conclusion: By the age of 60, participants with accelerated DNA methylation appear to have older, weaker, and more electrically impaired hearts. We show that the harmful effects of CV risk factors on cardiac age and health, appear to be partially mediated by DNAm AgeAccelPheno and AgeAccelGrim. This highlights the need to further investigate the potential cardioprotective effects of selective DNA methyltransferases modulators.

DNAmFitAge: biological age indicator incorporating physical fitness

Mortality Associations With DNA Methylation-Based Biological Aging and Physical Functioning Measures Across a 20-Year Follow-up Period

DNA methylation GrimAge strongly predicts lifespan and healthspan

Weight management intervention identifies association of decreased DNA methylation age with improved functional age measures in older adults with obesity

EPIGENETIC PREDICTORS OF LIFESPAN AND HEALTHSPAN

Quantification of the pace of biological aging in humans through a blood test: The DunedinPoAm DNA methylation algorithm

Alterations of the gut microbiome are associated with epigenetic age acceleration and physical fitness

Associations between cardiorespiratory fitness and lifestyle-related factors with DNA methylation-based ageing clocks in older men: WASEDA'S Health Study

An epigenetic biomarker of aging for lifespan and healthspan

DNA Methylation Clocks and Their Predictive Capacity for Aging Phenotypes and Healthspan

Epigenetic and Metabolomic Biomarkers for Biological Age: A Comparative Analysis of Mortality and Frailty Risk

DNAm-based Signatures of Accelerated Aging and Mortality in Blood Are Associated with Low Renal Function.

DNA methylation‐based biomarkers of aging were slowed down in a two‐year diet and physical activity intervention trial: the DAMA study

DNA Methylation-Based Biomarkers of Age Acceleration and All-Cause Death, Myocardial Infarction, Stroke, and Cancer in Two Cohorts: the NAS, and KORA F4

Fitness age outperforms body mass index in differentiating aging patterns and health risk profiles of healthy adults aged 51–80 years

Younger epigenetic age is associated with higher cardiorespiratory fitness in individuals with airflow limitation

DNAm aging biomarkers are responsive: Insights from 51 longevity interventional studies in humans

Genome-wide association studies identify 137 genetic loci for DNA methylation biomarkers of aging

A Comprehensive Assessment of Methylation-Based Age Prediction Methods

Accelerated DNA methylation age plays a role in the impact of cardiovascular risk factors on the human heart

Association of DNA methylation age acceleration with digital clock drawing test performance: the Framingham Heart Study